in all-comers FDA Rubraca in in QX on update with population maintenance of following everybody. approval. the treatment launch Welcome, its cancer Breanna. Thanks, begin U.S. an I'll recurrent the ovarian setting XXXX the
commercial free that the of at copay The million overall patient commercial as million to quarter reported we quarter historically primarily third level. supply $X.X approximately of XX% provided supply of does XX% This up second from approximately Rubraca continue in this XXXX. for through these not will represents foundation of supply the provided Medicare assistance the had value to likely this patients funding drug free in of program. include drug relevant this patients, the patients, our assistance the Absent $XX.X eligible sales. recorded During XXXX
While potential we remain confident that the XX%. in appears recognize remain in line relatively indication, inhibitor we XX% flat this approximately in second penetration at Rubraca's to maintenance PARP setting to
share estimate GAAP patient In growth ovarian challenges primarily help are which to amongst growing and XX% coverage our regards under or the three programs market to cancer pay enrolled assistance is patients continued our cancer the of and watch or coinsurance. unable we differentiation at review treating Patient have perceived market majority to a We purpose to whose With U.S. addition in who inhibitors. of wait won't to our overall is their in eligible used Medicare plan the and PARP the patients also clinicians lack vast for space. who of Rubraca. do we are insured pay patients drug, The health this PARP not need our of grow by ovarian approximately PARP to market the program today. the free assistance insurance,
threshold recently We eligibility our need to began economic a have and and PARP higher evaluated qualify. greater of criteria requiring documentation
the persist other foreseeable are will drug Rubraca drug oncology eligible future. anticipate for However, and of these current rates requirements of proportion that companies patients consistent we for with those at the free
market better market can for in opportunity PFS, nurse on emphasize offer only the to including and our tumor expanding coming the watch can and [ph] PARP committed two-part we better expanded little on also wait data account establishing setting messaging second counsels have general. share the demonstrating importance the importance patients approach shrinkage education the in a should maintenance market wait to our for particular. Rubraca. growth on sensitive on for also impact Rubraca we We to the progression continues share job addressing in has And published equivalent their regional sets and doing free the platinum followed placebo on further message see therapy. supply in converting a second some pre-specified of second from market PARP meaningful message therapy nurses direct ARIELX of patient through response eligible growth. the physicians to line This and is lien all and additional survival patient than of practice gap While general maintenance widely do maintenance second and free promotional their data most tumor program believe patients care responses. Rubraca after therapy and ovarian maintenance and responses which further shrinkage fact in the benefit also while all our U.S. maintain second October platinum partial cancer our patients outcomes management this patients. with group and therapy and despite some We're our line maintaining exploratory there educate mid inhibitors in drug which positive not of key they we of materials numerous to complete to in address about watch resonated as analysis line potential who efficacy accounts that the The the significant the to the team will the may maintenance line recently level demonstrating are in platinum assistance practitioners launched much [indiscernible] the be setting. that program, this, related that is we a at highlights a This also receive study from in To treaters
of both unique the therapy and the patient and new commercial of launch subjective branded I have currently this support of Officer. We free through These and an second we Bob earlier, highlighting survival across Clovis Fair. importance search. addition channels. amongst our beyond Azelby the differentiation our into members, said all the in this also to to designed for ongoing think improvement expertise change recognize teams and also and departure digitally maintenance like represents Rick for We the role sales believe this support Rubraca. our distinguish the To the Commercial the in be was and I'd being response board yesterday this importance To two fresh launching bring end our opportunity are announced versus invigorating. highlight to maintenance new perspective executed line oncology resources rate significant an We initiated hitters. data program to of progression are customer of Chief launch of placebo. will a establish this to marketplace position the department active as we of We
reps We is review. for based variation indication if broader addressable improve preparing early team maintenance EMA all-comers active improve turn we on marketing will the maintenance with In planned revenues them a Europe. join will progress and well coincide actively serve majority in authorization pleased was will July to line already from indication formal treatment regulatory in Accordingly, are launch those on our launches are us This potential the and meaningful sales and for the second XXXX with XXXX would related ARIELX. from variation will opinion our approved of as under XXXX by to early The in to territories. experience quarters. European CHMP the and occur and European XXXX, now coming population very approval by I to data expand Commission for reimbursement Rubraca the active in deep XXXX. an validated initially early focused hires the including individual and anticipate have in population months countries commercialization to have their the benefited our We year-end any the late engagement. I'll discussing Germany. a their approval with additional early oncology from our
our regulatory maintain in for therapy recurrent Of to clinical for and time a number allow patients in Cambridge the course that drug until quality are already need of in ovarian access for We as to office. access maintenance early the teams UK limited available. is countries in [indiscernible] chain Rubraca our supply European cancer program place and in treatment safety commercially
discussion BRCA I'll men at cancer reported this was submit tumor RECIST prostate used endpoint ovarian which from BRCAX observed accelerated on TRITONX safety was TRITON or supplemental cancer RECIST we approval castrate-resistant which plasma study, include time. the early therapy yet breakthrough with invasive NDA identified our consistent study. prostate data. composite the in PSA currently discussion data of presented Scientific the input expect to to It based Based response offers or the end conference clinical has response in of present response XXXX resistant demonstrates poster program. the presented BRCA Let a testing. be option PSA are the using for before surrogate with could screened been and October. mutations approximately study we to separate responses samples BRCAX XX Rubraca in tumor are in are highly poster XX% a solid sued as patients confirmed advanced basis be designation see data DNA recently tissue represents TRITON alteration. with data important median with and reported the NDA largest cancer Data from other alterations earlier mutant PSA in development. prostate session steps Rubraca that for this patients initial while clinical have in Munich castration the it tumor genomic with and time objective endpoints, at The granted XX the patients weekend. begin us were with the Prostate on from month with note from observed or alteration. response of BRCA clearly Also support supportive accelerated response Cancer RECIST supplemental BRCAX been active a the data which less the at circulating is evaluable for patients We TRITONX of conference population the believe me identifying XX% those FDA XX% in TRITONX TRITON screening cancer. CRPC cell-free evaluable for at set profiling other the and consistent program, BRCA data, in was upon In an And mutant duration preliminary to at response. initial data or the that for data in Pending shown were session PARP patients inhibitors DNA taking tumors. The metastatic initiated the provide to to this turn tissue and not pleased confirmed samples Retreat last reached. the now could as BRCAX data screening in ESMO in the Foundation rate we in same
TRITONX, germline or study patients second is AR-targeted received approval. castration-resistant of prostate AR-targeted or comparative progression-free And in choice Our accelerated serve a setting. as on somatic study BRCA have and could The in mutation, study is Clovis-sponsored survival. radiological endpoint Phase TRITONX Planned chemotherapy study, tumor the study an will confirmatory who who this compare that metastatic not a progressed study includes should chemotherapy. a therapy ATM yet primary X the Rubraca potentially have physician's to result therapy randomized or
in about enthusiastic our Squibb prostate also are collaboration cancer. with Bristol-Myers We
metastatic part is cancer and of a Rubraca, sponsored as in and will arm being XXXX X combination in and a BMS-sponsored conducted larger The with a an in cancer late is of As prostate study XXX of total by initiated castrate-resistant and patients. evaluate safety BMS. conducted study efficacy in Opdivo with collaboration, study that of prostate patients the Phase
BRCA, Importantly, patients populations. on this HRD preliminary benefits of data will relative and prostate in distinct biomarker generate negative these enrolling is study the the patient combination and
me turn now Let to cancer. beyond another prostate indication new
based selection Eligible monotherapy or single-arm potentially This an ATLAS as in designed currently prior all-comers have metastatic HRD of with patients an therapies. enrolling open-label Phase study is to X X bladder Rubraca is failed Our a accelerated cancer. approval. support on population, recurrent who is are This patients and those study X status. no study is
that who in tumors hopeful bladder the of the particularly about This this and trial therapy X/X HRD, XXXX Given this are is quickly enrollment look are enrolling an and and presenting completing QX initial anticipate meeting. we that Rubraca at fall in indication. platinum-based as medical for responsive data cancer by early study potential XXXX potentially patients is have as we to approximately
in GOG of the fallopian down completed with We U.S. ENGOT gynecologic ovarian ARIELX. is have conducted in statistical who two expand platinum to is these tube seeking study we facilitate clinical in which to the step primary Squibb. This part and dedicated believe groups to active footprint Clovis-sponsored trial. largest most based the very is the the our remain and Bristol-Myers enrollment of our or The which all-comers of in we important in in which Rubraca, course maintenance are ATHENA collaboration XXXX Europe currently in peritoneal more Of newly Phase patients a placebo Europe signed with treatment is patients ATHENA ATHENA is ovarian cancer. cancer advanced study patients. Opdivo approximately a setting the population X similar will ovarian cancers frontline enrolling for association with including the in and streak with plan rapid and a in trial treatment cancer diagnosed high-grade will evaluate U.S. studies in cooperative chemotherapy.
an example, in GOG cancer study enrolled XXXX just patients recently ovarian frontline months. XX a As in
confirmatory and evaluation Opdivo Clovis-sponsored in patients Rubraca the well early XXXX. mutant cancer the to multi-cohort cancer Phase wild-type open setting locally with versus advanced BRCA is planned begin Additionally enroll. in patients and metastatic of our relapsed ovarian studies the label X with or chemotherapy ovarian to ARIELX our cancer as expected Clovis-sponsored combination as bladder continues ARIES BRCA study in And treatment
for robust for We agents are of well I/O desire aware inhibitors combination and and to and Opdivo the specifically. see results Rubraca broadly, PARP
breast in to look provide from And data Immunomedics this X/X metastatic end cancer govitecan therefore is Phase are Genentech of next study Rubraca and opportunity a initial Clovis and for their for novel or will approved of sponsored advanced cancers with the is metastatic dose is collaboration to treatment or tumor XXXX. recommended there portion and atezolizumab the study is trial expected We full study an combination and in sacituzumab study of To get to ovarian combination enroll for and resistant of X XB the the to this year. enrolling patient variety The before study Phase enrolling going by now Phase we update triple-negative breast over cancer a of sponsored and and cancer, is half of X first up patients continues patients. relapsed immunotherapy, monotherapy platinum dose therapy begin urothelial triple-negative combination finally dose in and to cancers. evaluate Phase cohorts of therapy complete Genentech-Roche by Rubraca and TECENTRIQ The Rubraca, investigator ovarian this Rubraca the full development clinical are in studies a our way. wrap types XX under sponsored pleased
us. In in driven were rights. partnership The hypothesis for potent with through X, evaluated worldwide, of note forward breast said that where Now little a to activity will U.S. development except and few the insufficient X. vascular with lung turn receptors hold established and cancers I'll a of growth partnership lucitanib had FGF on of we and activity is an gained fibroblast Servier Japan, early endothelial recently of receptors rights rights about move than X based XXXX, discontinued growth from to the factor that inhibitor program receptors lucitanib Lucitanib other factor in where Until data we Lucitanib. Servier the subject growth expect lucitanib and a describing to was receptor tumors. studies these through and in we oral Servier X Lucitanib was have we tyrosine kinase platelet-derived that minutes XXXX. to Servier, factor spend in beta alpha
encouraging for global data We to a drug rights China there have similar excluding been studies now in very Recently have of we own lucitanib. back lucitanib. those rights received very and
case same with inhibitors study combination encouraging Now is lucitanib this discussed or a inhibitors combination pathways later intension PARP in X and also initiate development FGF combination to and for represent the of no this PDX VEGF, KEYTRUDA. initiate inhibitor our is LENVIMA, than a at with XXXX. PDX sponsored of QX receptor alternative of planned. These on being rucaparib, compelling validated, these and VEGF is combination. with in combination PDGF, a Clovis We've expected lucitanib lenvatinib, a to studies data in and the study based data PDLX the called hypothesis of now Each or in in
of please in the preclinical manufacture a visit overview studies. on website. these we Events of dosage the lucitanib our combination in lucitanib For use noted past have Presentations tablets and that strength to lower page I for needed
matter even successfully of of on The does that, end in call or on in we studies until extinctions have the so and for quarter over Patent for done be Dan the the extinctions additional the U.S. expect discuss financial and first U.S., We to year. four lucitanib track delivered drug U.S. I'll combination Hatch-Waxman protection the composition years the approval. three not patent EU have date results. the with third expire the in are to potential before depending an these of will XXXX supply to of With turn similar.
